77.5 B+

NAD+

Also known as: Nicotinamide adenine dinucleotide, NAD

Strong Clinical Evidence Research Chemical
Research Evidence 90.0/100
Safety Profile 65.0/100

60 Clinical Trials

Unknown: 11 PHASE4: 6 PHASE3: 11 PHASE2, PHASE3: 1 PHASE2: 7 PHASE1, PHASE2: 2 PHASE1: 3 NA: 18 EARLY_PHASE1: 1

Showing 5 of 60 trials.

20 Research Papers

Showing 5 of 20 papers by citation count.

FDA Data

Not FDA-Approved

NAD+ has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.

Frequently Asked Questions

Is NAD+ FDA approved?
No, NAD+ has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has NAD+ been studied in?
NAD+ has been studied in 60 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for NAD+?
NAD+ has a CheckPeptides trust score of 77.5/100 (grade: B+). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026

Quick Facts

Classification
Coenzyme / metabolic cofactor
Molecular Weight
663.4 Da
Regulatory Status
N/A

Score Breakdown

Research Evidence 90.0/100
Safety Profile 65.0/100

Evidence Summary

Clinical Trials
60
Research Papers
20
Trust Score
77.5/100
Grade
B+

Compare Peptides

See how NAD+ stacks up against similar peptides.

View Comparisons
← Browse all peptides